Last reviewed · How we verify
anti-CD 25 mAb, Sirolimus, MMF
Anti-CD 25 mAb targets and binds to the CD25 receptor on T cells, preventing their activation and proliferation.
Anti-CD 25 mAb targets and binds to the CD25 receptor on T cells, preventing their activation and proliferation. Used for Prevention of organ rejection in kidney transplant patients, Treatment of graft-versus-host disease.
At a glance
| Generic name | anti-CD 25 mAb, Sirolimus, MMF |
|---|---|
| Also known as | Rapamune, Simulect, CellCept, DecortinH |
| Sponsor | University of Regensburg |
| Drug class | Monoclonal antibody |
| Target | CD25 |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
This mechanism is based on the principle of immunosuppression, where the drug inhibits the activation of T cells, which play a key role in the immune response. By targeting CD25, a protein expressed on activated T cells, the drug reduces the immune response and prevents the rejection of transplanted organs or the progression of autoimmune diseases.
Approved indications
- Prevention of organ rejection in kidney transplant patients
- Treatment of graft-versus-host disease
Common side effects
- Thrombocytopenia
- Leukopenia
- Anemia
- Nausea
- Vomiting
Key clinical trials
- CNI-free de Novo Protocol in Patients Undergoing Liver Transplantation With Renal Impairment (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- anti-CD 25 mAb, Sirolimus, MMF CI brief — competitive landscape report
- anti-CD 25 mAb, Sirolimus, MMF updates RSS · CI watch RSS
- University of Regensburg portfolio CI